Suppr超能文献

相似文献

1
Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma.
Neuro Oncol. 2012 Apr;14(4):482-90. doi: 10.1093/neuonc/nos003. Epub 2012 Feb 8.
4
Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.
Ann Surg Oncol. 2008 Oct;15(10):2887-93. doi: 10.1245/s10434-008-0048-2. Epub 2008 Jul 18.
6
Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial.
Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275. doi: 10.1007/s00701-005-0707-z. Epub 2006 Feb 17.
7
Cerebral edema associated with Gliadel wafers: two case studies.
Neuro Oncol. 2005 Jan;7(1):84-9. doi: 10.1215/S1152851704000614.
9
Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
J Control Release. 2019 Feb 10;295:93-101. doi: 10.1016/j.jconrel.2018.12.048. Epub 2018 Dec 31.
10
The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis.
Drug Des Devel Ther. 2015 Jun 29;9:3341-8. doi: 10.2147/DDDT.S85943. eCollection 2015.

引用本文的文献

2
Recent Advances in the Biomedical Applications of Functionalized Nanogels.
Pharmaceutics. 2022 Dec 16;14(12):2832. doi: 10.3390/pharmaceutics14122832.
6
Safety of Gliadel Implant for Malignant Glioma: Report of Postmarketing Surveillance in Japan.
Neurol Med Chir (Tokyo). 2021 Sep 15;61(9):536-548. doi: 10.2176/nmc.oa.2021-0024. Epub 2021 Jul 9.
7
CEST MRI detectable liposomal hydrogels for multiparametric monitoring in the brain at 3T.
Theranostics. 2020 Jan 12;10(5):2215-2228. doi: 10.7150/thno.40146. eCollection 2020.
8
Development of bioactive materials for glioblastoma therapy.
Bioact Mater. 2016 Apr 23;1(1):29-38. doi: 10.1016/j.bioactmat.2016.03.003. eCollection 2016 Sep.
9
Incomplete copolymer degradation of in situ chemotherapy.
J Mater Sci Mater Med. 2018 Feb 17;29(3):25. doi: 10.1007/s10856-018-6032-x.

本文引用的文献

1
Pseudoprogression: relevance with respect to treatment of high-grade gliomas.
Curr Treat Options Oncol. 2011 Sep;12(3):240-52. doi: 10.1007/s11864-011-0157-1.
3
The first 3 months after BCNU wafers implantation in high-grade glioma patients: clinical and radiological considerations on a clinical series.
Acta Neurochir (Wien). 2010 Nov;152(11):1923-31. doi: 10.1007/s00701-010-0759-6. Epub 2010 Aug 13.
6
Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience.
Curr Med Res Opin. 2008 Nov;24(11):3239-57. doi: 10.1185/03007990802508180. Epub 2008 Oct 20.
7
Survival from brain tumours in England and Wales up to 2001.
Br J Cancer. 2008 Sep 23;99 Suppl 1(Suppl 1):S98-101. doi: 10.1038/sj.bjc.6604603.
8
Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Ann Oncol. 2008 May;19 Suppl 2:ii83-5. doi: 10.1093/annonc/mdn099.
9
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Expert Rev Anticancer Ther. 2008 Mar;8(3):343-59. doi: 10.1586/14737140.8.3.343.
10
French brain tumor data bank: methodology and first results on 10,000 cases.
J Neurooncol. 2007 Sep;84(2):189-99. doi: 10.1007/s11060-007-9356-9. Epub 2007 Apr 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验